Table 1.
Study | Design | Data collection (Months) | Sample size | Type of participants | Gender (% Women) | Age in years (SD) | Pathologies (%) | Quality STROBE/CONSORT |
---|---|---|---|---|---|---|---|---|
1. Sheridan et al. (2021) | ROS | 12 | 963 | P | 43 | 75.8 (NI) |
Cancer: 100 | 20 |
2. Cai et al. (2020) | POS | 26 | 290 | P, CG | P: 53.8 | P: 72.4 (12.38) | Cancer: 100 | 21 |
CG: 67.2 | CG: 59.3 (13.10) | |||||||
3. Skorstengaard et al. (2020) | RCT | 36 | N: 205 | P | 50 | 69 (NI) | Cancer: 50.1 | 21 |
n (intervention) 102 | Heart disease: 16.7 | |||||||
n (control): 103 | Lung disease: 33.2 | |||||||
4. Ali et al. (2019) | ROS | 60 | 2176 | P | NI | NI | Cancer: 88 | 18 |
Non-cancer: 22 | ||||||||
5. Blanchard et al. (2019) | ROS | 22 | 191 | P | 55.5 | 57.6 (13.26) | Cancer: 100 | 19 |
6. Wiggins et al. (2019) | ROS | 16 | 1047 | P | 64.6 | <79 (DT 13.8) | Cancer: 10.0 | 19 |
Cardiac disease: 4.4 | ||||||||
Vascular disease: 2.2 | ||||||||
Respiratory disease: 1.7 | ||||||||
Neurological disease: 1.6 | ||||||||
Dementia: 75.8 | ||||||||
Other: 4.3 | ||||||||
7. Bannon et al. (2018) | ROS | 6 | 467 (363 included in the analysis) | P | 60.6 | <69 (57.5%) | Cancer: 100 | 18 |
8. Chiba et al. (2018) | Mixed | 12 | 18 P/CG | P, CG, GP | P: 11.2 | P: 71.9 (12.4) | Cancer: 100 | 18 |
24 GP | CG: 94.4 | CG: 61.9 (12.9) | ||||||
GP: 16.7 | GP: NI | |||||||
9. Raijmakers et al. (2018) | ROS | 17 | 797 | P | P: 53.6 | P <65 57.6% | Cancer: 43.7 | 19 |
CG: 69.3 | CG <75 27.2% | Stroke: 12.4 | ||||||
COPD: 10.9 | ||||||||
Heart failure: 14.6 | ||||||||
Dementia: 26.5 | ||||||||
10. Higginson et al. (2017) | POS | 17 | 138 | P | 49 | 74 (NI) | Cancer: 88.0 | 18 |
Non-cancer: 12.0 | ||||||||
11. Lin et al. (2017) | ROS | 55 | 481 | P | 39.3 | 70.6 (14.3) | Cancer: 70.9 | 21 |
Non-cancer: 29.1 | ||||||||
12. Howell et al. (2017) | ROS | 36 | 323 | P | 44.9 | 72.4 (12.7) | Cancer (haematological): 100 | 21 |
13. de Graaf et al. (2016) | ROS | 6 | 130 | P | 52 | 72 (12.1) | Cancer: 89 | 21 |
Lung failure, COPD: 3 | ||||||||
Renal failure: 1 | ||||||||
ALS: 2 | ||||||||
Heart failure: 1 | ||||||||
Dementia: 1 | ||||||||
Other: 2 | ||||||||
14. Arnold et al. (2015) | ROS | 12 | 1127 | P | 50 | 70 (13) | Cancer: 94 | 15 |
Other: 6 | ||||||||
15. Burge et al. (2015) | ROS | 24 | 1316 (605 included in the analysis) | P | 51.3 | 79.1 (12.8) | Cancer: 38.1 Others: 61.9 |
21 |
16. Gage et al. (2015) | ROS | 18 | 688 | P | 43.6 | 75.10 (NI) | NI | 18 |
17. Ko et al. (2014) | ROS | 36 | 695 | P | 43,3 | ≥ 65: 67.9% | Cancer: 100 | 19 |
18. Hunt et al. (2014) | ROS | 7 | 1422 | P, CG | P: 34.6 | P: ≥ 60: 91.8% | Cancer: 34.6 | 20 |
CG: 64.9 | CG: ≥ 60: 55.5% | Cardiovascular disease: 24.9 | ||||||
Other: 40.5 | ||||||||
19. Aoun and Skett (2013) | POS | 18 | 43 (36 included in the analysis) | P | 49 | 74 (10.1) | Cancer: 100 | 20 |
20. Brogaard et al. (2013) | POS | 21 | 96 | P | 41.7 | 69.9 (NI) | Cancer: 100 | 20 |
21. Fischer et al. (2013) | POS | 29 | 458 | P | 35 | 57.9 (14.8) | Cancer: 11 | 18 |
Other: 89 | ||||||||
22. Janssen et al. (2013) | POS | 24 | 265 (206 included in the analysis) | P | 35.9 | 67.2 (13.1) | COPD: 41.8 | 21 |
Chronic heart failure: 29.6 | ||||||||
Chronic renal failure: 28.6 | ||||||||
23. Capel et al. (2012) | POS | 24 | 788 | P | NI | NI | Cancer: 93 | 21 |
Non-cancer: 7 | ||||||||
24. Johnson et al. (2012) | POS | 15 | 126 (80 included in the analysis) | P | 38 | 78 (10.7) | Chronic heart failure: 100 | 21 |
25. Abarshi et al. (2011) | ROS | 12 | 252 (165 included in the analysis) | P | 55 | > 65: 80% | Cancer: 38 | 20 |
Non-cancer: 62 | ||||||||
26. Alonso-Babarro et al. (2011) | POS | 36 | 380 (228 included in the analysis) | P, CG | P: 39.5 | P: 66.76 (13.4) | Cancer: 100 | 20 |
CG: 17.9 | CG: 54,32 (14.4) | |||||||
27. Escobar Pinzon et al. (2011) | CS | 4 | 1378 | P, CG | P:55.6 | P: 77.6 (13.2) | Cancer: 24.2 | 21 |
CG: 63.4 | CG: 58.8 (12.8) | Dementia: 8.9 | ||||||
Cardiovascular disease: 8.4 | ||||||||
Other: 12.0 | ||||||||
Multimorbidity: 36.6 | ||||||||
Missing/I don't know: 9.9 | ||||||||
28. Gerrard et al. (2011) | ROS | 2007: 6 | n (2007): 236 | P | 2007: 50.5 | 2007: 78 (NI) | 2007: Cancer: 66 | 20 |
2009: 6 | n (2009): 275 | Other: 34 | ||||||
Total: 511 | 2009: 42.0 | 2009: 72 (NI) | 2009: Cancer: 76 | |||||
Other: 24 | ||||||||
29. Walker et al. (2011) | ROS | 24 | 150 | P | NI | NI | NI | 19 |
30. Holdsworth and Fisher (2010) | ROS | 6 | 298 | P | NI | NI | Cancer: 80 | 18 |
Other: 20 |
RCT, randomised controlled trial; ROS, retrospective observational study; POS, prospective observational study; CS, cross-sectional study; COPD, chronic obstructive pulmonary disease; ALS, amyotrophic lateral sclerosis; NI, no information; RRS, rapid response service; P, patient; CG, caregivers; GP, general practitioners.